Results 61 to 70 of about 47,791 (152)

A Large-Scale CNN Ensemble for Medication Safety Analysis

, 2017
Revealing Adverse Drug Reactions (ADR) is an essential part of post-marketing drug surveillance, and data from health-related forums and medical communities can be of a great significance for estimating such effects.
A Sarker, A Sarker, H Gurulingappa, WYS Chou   +3 more
core   +1 more source

The Future of Generic Biologics: Should the United States “Follow-On” the European Pathway? [PDF]

, 2008
The United States is embarking on a biotechnology drug revolution. In the last few decades, biotech drugs have saved millions of lives, and the market for these miracle cures continues to grow at an astronomical rate.
Aili, Daniel, Baltzer, Lars, Liedberg, Bo, Selegård, Robert, Tay, Yeeyan, Wang, Yusong, Zhang, Hua   +6 more
core   +3 more sources

Drug‐induced sarcoidosis: an overview of the WHO pharmacovigilance database

Journal of Internal Medicine, 2020
There is a documented association between drug exposure and sarcoidosis‐like reactions. In this study, we used the largest pharmacovigilance database to describe drug‐induced sarcoidosis.
F. Cohen Aubart, R. Lhote, A. Amoura, D. Valeyre, J. Haroche, Z. Amoura, B. Lebrun-Vignes   +6 more
semanticscholar   +1 more source

A Framework of National Pharmacovigilance System for Developing Countries [PDF]

Pharmacovigilance is defined as “the science and activities related to the detection, assessment, understanding, and prevention of adverse drug reactions or any other drug-related problems”.
Asadi, Farkhondeh, Hosseini, Azamossadat, Moghaddasi, Hamid, Nikookalam, Maryam, Zarghi, Afshin   +4 more
core   +2 more sources

Electronic health records to facilitate clinical research [PDF]

, 2016
Electronic health records (EHRs) provide opportunities to enhance patient care, embed performance measures in clinical practice, and facilitate clinical research. Concerns have been raised about the increasing recruitment challenges in trials, burdensome
Blomster, Juuso I., Cowie, Martin R., Curtis, Lesley H., Duclaux, Sylvie, Ford, Ian, Fritz, Fleur, Goldman, Samantha, Janmohamed, Salim, Kreuzer, Jörg, Leenay, Mark, Michel, Alexander, Ong, Seleen, Pell, Jill P., Southworth, Mary Ross, Stough, Wendy Gattis, Thoenes, Martin, Zalewski, Andrew, Zannad, Faiez   +17 more
core   +2 more sources

Pharmacovigilance. / Erfahrungen seit der Reorganisation am 1. Juni 2001 [PDF]

, 2002
R Stoller
openalex   +3 more sources

DeepADEMiner: a deep learning pharmacovigilance pipeline for extraction and normalization of adverse drug event mentions on Twitter

medRxiv, 2020
Objective: Research on pharmacovigilance from social media data has focused on mining adverse drug effects (ADEs) using annotated datasets, with publications generally focusing on one of three tasks: (i) ADE classification, (ii) named entity recognition (
A. Magge, E. Tutubalina, Z. Miftahutdinov, I. Alimova, A. Dirkson, S. Verberne, D. Weissenbacher, G. Gonzalez-Hernandez   +7 more
semanticscholar   +1 more source

Future of ChatGPT in Pharmacovigilance

Drug Safety, 2023
Hanyin Wang, Y. Ding, Yuan-Zhi Luo
semanticscholar   +1 more source

Can the Heinrich ratio be used to predict harm from medication errors? [PDF]

, 2006
The purpose of this study was to establish whether, for medication errors, there exists a fixed Heinrich ratio between the number of incidents which did not result in harm, the number that caused minor harm, and the number that caused serious harm.
Barber, N, Franklin, BD, Gallivan, S, Taxis, K   +3 more
core  

Proceedings of the biosimilars workshop at the International Symposium on Oncology Pharmacy Practice 2019. [PDF]

, 2020
The International Society of Oncology Pharmacy Practitioners organized a workshop to create learning opportunities on biosimilars in pharmacy practice on 10 October 2019.
Chan, Alexandre, Ke, Yu, Tan, Chia Jie
core